Anterogen to sell stem cell treatment

Published: 2011-09-19 06:57:00

Updated: 2011-09-19 06:57:00

Anterogen, a Korean biotechnology venture, filed an application with the Korea Food and Drug Administration Thursday to market a new drug “Cupistem”, a stem cell treatment for anal fistula in Crohn’s disease.

Crohn’s disease causes chronic inflammation of intestines along with ulcers. Severe u...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK